Skip to Main Content

Biogen’s announcement on Tuesday that it is “substantially eliminating” its spending on Aduhelm caps a remarkable story of drug development gone bad.

In a controversial move in June 2021, the Food and Drug Administration approved the Alzheimer’s drug, disregarding the strong objections of a panel of independent experts that said the science didn’t support approving the drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment